Castration-Resistant Prostate Carcinoma Clinical Trials

17 recruiting

Castration-Resistant Prostate Carcinoma Trials at a Glance

20 actively recruiting trials for castration-resistant prostate carcinoma are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in Seattle, Oklahoma City, and San Francisco. Lead sponsors running castration-resistant prostate carcinoma studies include University of Washington, Fred Hutchinson Cancer Center, and Jonsson Comprehensive Cancer Center.

Browse castration-resistant prostate carcinoma trials by phase

Treatments under study

About Castration-Resistant Prostate Carcinoma Clinical Trials

Looking for clinical trials for Castration-Resistant Prostate Carcinoma? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Castration-Resistant Prostate Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Castration-Resistant Prostate Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1Phase 2

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 1

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Roswell Park Cancer Institute14 enrolled1 locationNCT06305598
Recruiting
Not Applicable

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Metastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell Carcinoma+15 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04693377
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 1Phase 2

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8+2 more
Vadim S Koshkin30 enrolled1 locationNCT05113537
Recruiting
Phase 1Phase 2

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
University of Michigan Rogel Cancer Center39 enrolled3 locationsNCT06616155
Recruiting
Phase 2

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Alliance for Clinical Trials in Oncology474 enrolled101 locationsNCT06632977
Recruiting
Phase 1

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8+2 more
Jonsson Comprehensive Cancer Center30 enrolled1 locationNCT05398302
Recruiting
Phase 2

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Stage IVB Prostate Cancer AJCC v8Metastatic Castration-Resistant Prostate Carcinoma
University of Washington51 enrolled3 locationsNCT06526299
Recruiting
Phase 2

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Jonsson Comprehensive Cancer Center40 enrolled1 locationNCT06288113
Recruiting

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8+1 more
University of Washington48 enrolled4 locationsNCT04489719
Recruiting
Phase 1Phase 2

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
Fred Hutchinson Cancer Center48 enrolled1 locationNCT06236139
Recruiting
Phase 2

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
Fred Hutchinson Cancer Center15 enrolled1 locationNCT06145633
Recruiting
Phase 3

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
SWOG Cancer Research Network528 enrolled174 locationsNCT06470243
Recruiting
Phase 2

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
University of Washington69 enrolled1 locationNCT06039371
Recruiting
Phase 1

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
City of Hope Medical Center21 enrolled1 locationNCT05805371
Recruiting
Phase 2

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Mayo Clinic236 enrolled1 locationNCT06200103
Recruiting

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Metastatic Castration-Resistant Prostate Carcinoma
University of Michigan Rogel Cancer Center60 enrolled1 locationNCT07096999
Recruiting
Phase 1

Imaging of Solid Tumors Using 18F-TRX

Metastatic Malignant Solid NeoplasmStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+7 more
Rahul Aggarwal56 enrolled1 locationNCT06942104
Recruiting
Phase 2

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8+2 more
University of Utah33 enrolled1 locationNCT05168618